Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression

Description

Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these stress-related biomarkers predict TNR to a 12-week trial of either fluoxetine or escitalopram, and whether these stress-related biomarkers predict 18-month clinical course.

Conditions

Depression in Adolescence

Talk to us

Study Overview

On this page

Study Details

Study overview

Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these stress-related biomarkers predict TNR to a 12-week trial of either fluoxetine or escitalopram, and whether these stress-related biomarkers predict 18-month clinical course.

Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression: Toward Predictors of Treatment Response and Clinical Course

Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression

Condition
Depression in Adolescence
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * DSM-V criteria for a depressive disorder
  • * All sexes and genders
  • * All ethnicities
  • * Ages 14-21
  • * Postpubertal (Tanner stage \> 3)
  • * No medications that will interfere with the study (including antidepressants, mood stabilizers, hormone supplements, steroids, etc.) for at least 2-6 weeks (depending on exact medication)
  • * Currently being seen by a clinician who will treat the participant with fluoxetine or escitalopram
  • * The ability to provide assent, understand, and complete all study procedures
  • * Caregiver consent (if applicable)
  • * Primary mental health diagnosis other than a depressive disorder according to DSM-V
  • * Any contraindications to MRI scanning, phlebotomy, or SSRI treatment
  • * Stimulant usage
  • * A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes
  • * Any inflammatory conditions or use of anti-inflammatory medications that may influence study findings
  • * Any major neurological or developmental disorders which could impact the participant's ability to comply with study procedure
  • * Meeting for current or lifetime criteria of mania or psychosis, diagnosis of bipolar disorder, or any substance use disorders
  • * First-degree relative with current, past, or suspected mania or psychosis

Ages Eligible for Study

14 Years to 21 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Los Angeles,

Tiffany Ho, Ph.D., PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

2028-04-30